Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM [Yahoo! Finance]
Immunovant, Inc. (IMVT)
Company Research
Source: Yahoo! Finance
Today, a brief rundown of news from Immunovant and Alto Neuroscience, as well as updates from Oric Pharmaceuticals, Korsana Biosciences and a couple genetic medicine developers you may have missed. Shares for Immunovant , a Roivant spinout, fell Thursday after the company announced its experimental therapy for thyroid eye disease failed two late-stage trials. The company said batoclimab its drug in development with partner HanAllBiopharma, did not meet the Phase 3 trials' key goals, which centered on a reduction in eye swelling for adults with active thyroid disease. Immunovant said safety data was consistent with previous findings, and no new safety signals were identified. The company did not share detailed results. The partners said they will review plans for their candidate and provide updates at a later date. — Delilah Alvarado An experimental drug from Alto Neuroscience has failed a so-called proof-of-concept study evaluating it as a treatment for the cognitive impairment a
Show less
Read more
Impact Snapshot
Event Time:
IMVT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMVT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMVT alerts
High impacting Immunovant, Inc. news events
Weekly update
A roundup of the hottest topics
IMVT
News
- Immunovant Batoclimab Flops in Phase 3 TED as Roivant Expands Brepocitinib Into LPP [Yahoo! Finance]Yahoo! Finance
- Immunovant shares plunge after phase 3 trials fails to meet primary endpoint [Yahoo! Finance]Yahoo! Finance
- Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) [Yahoo! Finance]Yahoo! Finance
- Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) [Yahoo! Finance]Yahoo! Finance
- Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)GlobeNewswire
IMVT
Earnings
- 2/6/26 - Beat
IMVT
Sec Filings
- 4/3/26 - Form 4
- 3/20/26 - Form 4
- 2/27/26 - Form 4
- IMVT's page on the SEC website